28 October 2025
The Medicines and Healthcare products Regulatory Agency (MHRA) has announced on behalf of the ILAP Partners, that three potential therapies have become the first to enter a new UK scheme designed to help promising new medicines reach NHS patients faster and have been awarded 'Innovation Passports'. The ILAP Partners are the MHRA, the National Health Service and the health technology assessment (HTA) bodies – the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC).
ILAP is the only end-to-end pathway in the world where healthcare developers, the regulator, the UK-wide national health system, and the health technology assessment (HTA) bodies work together from the outset. By giving developers early, coordinated guidance on safety, effectiveness and value requirements across the system, the scheme is designed to reduce the time it takes for promising new treatments to move through development, licensing and, if approved, to NHS patients.
More about the three medicines awarded an Innovation Passport and about ILAP is available from the MHRA website at www.gov.uk/government/news/the-new-innovative-licensing-and-access-pathway-welcomes-first-investigational-products